Studies have shown that DC661 has the strongest lysosomal-inhibition compared with other monomer or dimer chloroquine (CQ) derivatives [14], suggesting that the targeting of PPT1 expression in combination with sorafenib treatment for HCC is a potentially valuable therapeutic strategy. The gene discussed is PPT1; the disease is hepatocellular carcinoma.